Long-Term Outcome in Systemic Lupus Erythematosus; Knowledge from Population-Based Cohorts

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Oct 13

PMID 34640322

Citations 5

Authors

Sigrid Reppe Moe

Hilde Haukeland

Oyvind Molberg

Karoline Lerang

Affiliations

Soon will be listed here.

Abstract

Background: Accurate knowledge of outcomes in Systemic Lupus Erythematosus (SLE) is crucial to understanding the true burden of the disease. The main objective of this systematic review was to gather all population-based studies on mortality, end-stage renal disease (ESRD) and cancer in SLE.

Method: We performed a systematic literature search in two electronic databases (MEDLINE and Embase) to identify all population-based articles on SLE and survival, mortality, ESRD and cancer. The SLE diagnosis had to be verified. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA).

Results: We included 40/1041 articles on mortality (27), ESRD (11) and cancer (3), of which six were defined as inception studies. In the total SLE cohort, the standardized mortality ratio ranged from 1.9 to 4.6. Cardiovascular disease was the most frequent cause of death in studies with follow-up times over 15 years. SLE progressed to ESRD in 5-11% of all SLE patients. There are no data supporting increased cancer incidence from population-based inception cohorts.

Conclusion: There is a need for more population-based studies on outcomes of SLE, especially inception studies, with the use of control groups and follow-up times over 15 years.

Citing Articles

Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus.

Nikolopoulos D, Lourenco M, Depascale R, Triantafyllias K, Parodis I Mediterr J Rheumatol. 2024; 35(Suppl 2):328-341.

PMID: 39193182 PMC: 11345603. DOI: 10.31138/mjr.290424.eci.

Persisting mortality gap in systemic lupus erythematosus; a population-based study on juvenile- and adult-onset SLE in Norway 1999-2022.

Moe S, Haukeland H, Brunborg C, Botea A, Damjanic N, Wivestad G Rheumatology (Oxford). 2023; 63(8):2109-2117.

PMID: 37769251 PMC: 11292052. DOI: 10.1093/rheumatology/kead519.

Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus Erythematosus.

Sjowall C, Parodis I J Clin Med. 2022; 11(22).

PMID: 36431345 PMC: 9695498. DOI: 10.3390/jcm11226869.

Mendelian randomization and pathway analysis demonstrate shared genetic associations between lupus and coronary artery disease.

Kain J, Owen K, Marion M, Langefeld C, Grammer A, Lipsky P Cell Rep Med. 2022; 3(11):100805.

PMID: 36334592 PMC: 9729823. DOI: 10.1016/j.xcrm.2022.100805.

Patient-Reported Outcomes in Systemic Lupus Erythematosus. Can Lupus Patients Take the Driver's Seat in Their Disease Monitoring?.

Parodis I, Studenic P J Clin Med. 2022; 11(2).

PMID: 35054036 PMC: 8778558. DOI: 10.3390/jcm11020340.

References

Mok C, To C, Ho L, Yu K . Incidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000-2006. J Rheumatol. 2008; 35(10):1978-82. View

Ragnarsson O, Grondal G, Steinsson K . Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus. 2003; 12(9):687-91. DOI: 10.1191/0961203303lu443oa. View

Alamanos Y, Voulgari P, Siozos C, Katsimpri P, Tsintzos S, Dimou G . Epidemiology of systemic lupus erythematosus in northwest Greece 1982-2001. J Rheumatol. 2003; 30(4):731-5. View

Lee Y, Choi S, Ji J, Song G . Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016; 25(7):727-34. DOI: 10.1177/0961203315627202. View

Schoenfeld S, Kasturi S, Costenbader K . The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013; 43(1):77-95. DOI: 10.1016/j.semarthrit.2012.12.002. View

Jacobsen S, Petersen J, Ullman S, Junker P, Voss A, Rasmussen J . A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets. Clin Rheumatol. 1999; 17(6):468-77. DOI: 10.1007/BF01451282. View

Chen Y, Chang Y, Wang C, Wu C . Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med. 2010; 123(12):1150.e1-6. DOI: 10.1016/j.amjmed.2010.08.006. View

Lucero L, Barbaglia A, Bellomio V, Bertolaccini M, Machado Escobar M, Sueldo H . Prevalence and incidence of systemic lupus erythematosus in Tucumán, Argentina. Lupus. 2020; 29(13):1815-1820. DOI: 10.1177/0961203320957719. View

Naleway A, Davis M, Greenlee R, Wilson D, McCarty D . Epidemiology of systemic lupus erythematosus in rural Wisconsin. Lupus. 2005; 14(10):862-6. DOI: 10.1191/0961203305lu2182xx. View

10.

Mok C, Mak A, Chu W, To C, Wong S . Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. Medicine (Baltimore). 2005; 84(4):218-224. DOI: 10.1097/01.md.0000170022.44998.d1. View

11.

Gergianaki I, Fanouriakis A, Repa A, Tzanakakis M, Adamichou C, Pompieri A . Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Ann Rheum Dis. 2017; 76(12):1992-2000. DOI: 10.1136/annrheumdis-2017-211206. View

12.

Choi M, Flood K, Bernatsky S, Ramsey-Goldman R, Clarke A . A review on SLE and malignancy. Best Pract Res Clin Rheumatol. 2017; 31(3):373-396. PMC: 6742439. DOI: 10.1016/j.berh.2017.09.013. View

13.

Laustrup H, Voss A, Green A, Junker P . Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. Scand J Rheumatol. 2009; 38(2):128-32. DOI: 10.1080/03009740802419073. View

14.

Rees F, Doherty M, Grainge M, Lanyon P, Zhang W . The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017; 56(11):1945-1961. DOI: 10.1093/rheumatology/kex260. View

15.

Lu X, Wang Y, Zhang J, Pu D, Hu N, Luo J . Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: A systematic review and Meta-analysis. Int Immunopharmacol. 2021; 94:107466. DOI: 10.1016/j.intimp.2021.107466. View

16.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

17.

Gudmundsson S, Steinsson K . Systemic lupus erythematosus in Iceland 1975 through 1984. A nationwide epidemiological study in an unselected population. J Rheumatol. 1990; 17(9):1162-7. View

18.

Lu L, Wallace D, Ishimori M, Scofield R, Weisman M . Review: Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus. 2009; 19(2):119-29. PMC: 7304291. DOI: 10.1177/0961203309350755. View

19.

Lin W, Guo C, Wang W, Yang D, Kuo T, Liu M . Incidence of progression from newly diagnosed systemic lupus erythematosus to end stage renal disease and all-cause mortality: a nationwide cohort study in Taiwan. Int J Rheum Dis. 2014; 16(6):747-53. DOI: 10.1111/1756-185X.12208. View

20.

Bartels C, Buhr K, Goldberg J, Bell C, Visekruna M, Nekkanti S . Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol. 2014; 41(4):680-7. PMC: 3975689. DOI: 10.3899/jrheum.130874. View